Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Ceapro Inc V.CZO

Ceapro Inc. is a Canada-based biotechnology company. The Company is involved in the development of extraction technology and the application of this technology to the production of extracts and active ingredients from oats and other renewable plant resources. Its primary business activities relate to the development and commercialization of natural products for personal care, cosmetic, human... see more

TSXV:CZO - Post Discussion

Ceapro Inc > New research today... COVID, the heart, and inflammation...
View:
Post by prophetoffactz on Sep 28, 2023 10:54pm

New research today... COVID, the heart, and inflammation...

As Gilles noted the avenanthramide clinical trial will focus on COVID, longCOVID and the heart. Today new research was published... 


Thursday, September 28, 2023

SARS-CoV-2 infects coronary arteries, increases plaque inflammation

NIH-funded research sheds light on link between COVID-19 infection and increased risk of cardiovascular disease and stroke.

SARS-CoV-2, the virus that causes COVID-19, can directly infect the arteries of the heart and cause the fatty plaque inside arteries to become highly inflamed, increasing the risk of heart attack and stroke, according to a study funded by the National Institutes of Health. The findings(link is external), published in the journal Nature Cardiovascular Research, may help explain why certain people who get COVID-19 have a greater chance of developing cardiovascular disease, or if they already have it, develop more heart-related complications.

In the study, researchers focused on older people with fatty buildup, known as atherosclerotic plaque, who died from COVID-19. However, because the researchers found the virus infects and replicates in the arteries no matter the levels of plaque, the findings could have broader implications for anybody who gets COVID-19.

“Since the early days of the pandemic, we have known that people who had COVID-19 have an increased risk for cardiovascular disease or stroke up to one year after infection,” said Michelle Olive, Ph.D., acting associate director of the Basic and Early Translational Research Program at the National Heart, Lung, and Blood Institute (NHLBI), part of NIH. “We believe we have uncovered one of the reasons why.”

Though previous studies have shown that SARS-CoV-2 can directly infect tissues such as the brain and lungs, less was known about its effect on the coronary arteries. Researchers knew that after the virus reaches the cells, the body’s immune system sends in white blood cells known as macrophages to help clear the virus. In the arteries, macrophages also help remove cholesterol, and when they become overloaded with cholesterol, they morph into a specialized type of cell called foam cells.

The researchers thought that if SARS-CoV-2 could directly infect arterial cells, the macrophages that normally are turned loose might increase inflammation in the existing plaque, explained Chiara Giannarelli, M.D., Ph.D., associate professor in the departments of medicine and pathology at New York University’s Grossman School of Medicine and senior author on the study. To test their theory, Giannarelli and her team took tissue from the coronary arteries and plaque of people who had died from COVID-19 and confirmed the virus was in those tissues. Then they took arterial and plaque cells – including macrophages and foam cells – from healthy patients and infected them with SARS-CoV-2 in a lab dish. They found that the virus had also infected those cells and tissues.

Additionally, the researchers found that when they compared the infection rates of SARS-CoV-2, they showed that the virus infects macrophages at a higher rate than other arterial cells. Cholesterol-laden foam cells were the most susceptible to infection and unable to readily clear the virus. This suggested that foam cells might act as a reservoir of SARS-CoV-2 in the atherosclerotic plaque. Having more build-up of plaque, and thus a greater number of foam cells, could increase the severity or persistence of COVID-19.

The researchers then turned their attention to the inflammation they predicted might occur in the plaque after infecting it with the virus. They quickly documented the release of molecules, known as cytokines, that are known to increase inflammation and promote the formation of even more plaque. The cytokines were released by infected macrophages and foam cells. The researchers said this may help explain why people who have underlying plaque buildup and then get COVID-19 may have cardiovascular complications long after getting the infection.  

“This study is incredibly important as it adds to the larger body of work to better understand COVID-19,” said Olive. “This is just one more study that demonstrates how the virus both infects and causes inflammation in many cells and tissues throughout the body. Ultimately, this is information that will inform future research on both acute and Long COVID.”

Though the findings conclusively show that SARS-CoV-2 can infect and replicate in the macrophages of plaques and arterial cells, they are only relevant to the original strains of SARS-CoV-2 that circulated in New York City between May 2020 and May 2021. The study was conducted in a small cohort of older individuals, all of whom had atherosclerosis and other medical conditions; therefore, the results cannot be generalized to younger, healthy individuals.

This work was funded by the NIH/NHLBI grants 1R01HL165258, R01HL153712, R35HL135799 and R01HL084312. NIAID and NIDDK also provided funding.

About the National Heart, Lung, and Blood Institute (NHLBI): NHLBI is the global leader in conducting and supporting research in heart, lung, and blood diseases and sleep disorders that advances scientific knowledge, improves public health, and saves lives. For more information, visit www.nhlbi.nih.gov.

About the National Institutes of Health (NIH): NIH, the nation's medical research agency, includes 27 Institutes and Centers and is a component of the U.S. Department of Health and Human Services. NIH is the primary federal agency conducting and supporting basic, clinical, and translational medical research, and is investigating the causes, treatments, and cures for both common and rare diseases. For more information about NIH and its programs, visit www.nih.gov.

Comment by prophetoffactz on Sep 29, 2023 5:49am
Referenced new research published yesterday: "SARS-CoV-2, the virus that causes COVID-19, can directly infect the arteries of the heart and cause the fatty plaque inside arteries to become highly inflamed, increasing the risk of heart attack and stroke,"  CZO's avenanthramide malting technology could be used for a neutraceutical... There is also the avenanthramide pill ...more  
Comment by prophetoffactz on Sep 29, 2023 6:23am
"Our findings provide for the first time a direct mechanistic link between Covid-19 infection and the heart complications it provokes," said lead author Natalia Eberhardt, Postdoctoral fellow in the Department of Medicine at NYU Langone Health. "The virus creates a highly inflammatory environment that could make it easier for plaque to grow, rupture, and block blood flow to ...more  
Comment by prophetoffactz on Sep 29, 2023 7:47am
So, as the avenanthramide clinical trial is set to potentially begin recruitment/enrollment in 1 1/2 months does CZO have a potential therapeutic that could hit key biomarkers such as IL-6, IL-1β, reduce aortic lesions, and impact blood vessel damage at the cellular level? Aug. 23, 2021: “Endothelial cell stimulation is a hallmark of, and a requirement for, wound healing,” commented Dr. Vincent ...more  
Comment by prophetoffactz on Sep 29, 2023 10:22am
"Our findings provide for the first time a direct mechanistic link between Covid-19 infection and the heart complications it provokes," said lead author Natalia Eberhardt, Postdoctoral fellow in the Department of Medicine at NYU Langone Health. "The virus creates a highly inflammatory environment that could make it easier for plaque to grow, rupture, and block blood flow to ...more  
Comment by prophetoffactz on Sep 29, 2023 12:06pm
Tranilast is a synthetic avenanthramide and for this publication 15,000 drugs were screened. Tranilast was selected as a lead for COVID inhibition. Could CZO have a natural product that helps with COVID inflammation, reduces aortic lesions, assists with blood vessel healing, and inhibits the COVID virus? "The high rate of variant evolution makes clear the need for new therapeutics that can ...more  
Comment by prophetoffactz on Sep 29, 2023 5:38pm
If avenanthramide has a better safety profile and can help manage glucose and contribute to wound healing, etc., it could be interesting. 
Comment by prophetoffactz on Sep 30, 2023 9:55am
For the first itme COVID has now been discovered to infect arteries in the heart. While repeated infection of the heart could be a long term issue for anyone infected by COVID for as Dr. Li has warned COVID can damage blood vessels this new research has shown that COVID infection inflames plaques due to coronary heart disease which can further damage blood vessels. People had been ...more  
Comment by prophetoffactz on Sep 30, 2023 2:51pm
The avenanthramide malting technology CZO has now scaled to small-scale commercial production could be used for functional foods that include beta glucan. Beta glucan works to reduce LDL and help control plaques. What about PGX-OBG/Avenanthramide? --------- "The virus creates a highly inflammatory environment that could make it easier for plaque to grow, rupture, and block blood flow to the ...more  
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities